Document is current
Any future updates will be listed below
-
Authors
Imahashi, Nobuhiko https://orcid.org/0000-0002-1398-2002
Terakura, Seitaro https://orcid.org/0000-0002-1194-8046
Kondo, Eisei https://orcid.org/0000-0003-0995-9405
Kato, Koji
Kim, Sung-Won
Shinohara, Akihito https://orcid.org/0000-0002-5530-6133
Watanabe, Mizuki https://orcid.org/0000-0002-4030-4653
Fukuda, Takahiro
Uchida, Naoyuki https://orcid.org/0000-0001-5952-5926
Kobayashi, Hikaru
Ishikawa, Jun
Kataoka, Keisuke
Shiratori, Souichi https://orcid.org/0000-0002-5528-7112
Ikeda, Takashi https://orcid.org/0000-0003-3976-5230
Matsuoka, Ken-ichi https://orcid.org/0000-0001-7955-8266
Yoshida, Shuro
Kondo, Tadakazu https://orcid.org/0000-0002-8959-6271
Kimura, Takafumi
Onizuka, Makoto https://orcid.org/0000-0003-3864-0823
Ichinohe, Tatsuo https://orcid.org/0000-0002-0393-4066
Atsuta, Yoshiko https://orcid.org/0000-0003-4404-2870
Kanda, Junya https://orcid.org/0000-0002-6704-3633
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (19K17854)
Japan Agency for Medical Research and Development (19ek0510023h0002)
- License Information
-
More Information
Article History
Received: 11 August 2021
Revised: 22 October 2021
Accepted: 28 October 2021
First Online: 24 November 2021
Competing interests
: EK received speaker honoraria from Sumitomo Dainippon Pharma Co. and Takeda Pharmaceutical Co. T. Ichinohe has received speaker honoraria from Bristol-Myers Squibb, Celgene, Janssen Pharmaceutical K.K., and Kyowa Kirin Co. and research funding from Astellas Pharma, Chugai Pharmaceutical Co., CSL Behring, Eisai Co., FUJIFILM Wako Chemicals., Kyowa Kirin Co., Ono Pharmaceutical Co., Pfizer, Nippon Shinyaku Co., MSD, Otsuka Pharmaceutical Co., Repertoire Genesis Inc., Sumitomo Dainippon Pharma Co., Taiho Pharmaceutical Co., Takara Bio Inc., Takeda Pharmaceutical Co., and Zenyaku Kogyo Co. The other authors declare no competing interests.
